Comparative Study of Efficacy of Intralesional Purified Protein Derivative (PPD) Versus Intralesional Measles, Mumps, and Rubella (MMR) Vaccine in Management of Multiple Viral Warts

Overview

Journal J Cutan Aesthet Surg

Date 2022 Mar 14

PMID 35283602

Authors

Krishna B Bhalala

Shital Poojary

Kapisha Sunny Shah

Affiliations

Soon will be listed here.

Abstract

Background: Multiple viral warts represent a frustrating challenge for both patients and physicians. Management is difficult, primarily due to recalcitrance to standard therapy and high recurrence rates. Recently, intralesional antigen immunotherapy has shown promising efficacy in the treatment of warts.

Objective: The aim of our study was to compare efficacy and safety of intralesional PPD versus measles, mumps, and rubella (MMR) vaccine in the management of multiple warts.

Materials And Methods: One hundred and five patients having multiple warts were randomly divided into group A (PPD), group B (MMR) and group C (normal saline), with 35 patients in each group. In each group, the largest wart was injected intralesionally with 0.1 mL of vaccine at 2 weeks interval until complete clearance or for a maximum of 8 weeks.

Results: Out of 105 patients enrolled in the study, 27, 25, and 21 patients completed the study in group A, group B, and group C, respectively. Rest were lost to follow up due to various reasons such as pain and long treatment duration. Complete clearance was seen in 14 patients (51.85%) in group A, 14 patients (56%) in group B, and 0 patients in group C. Partial clearance was seen in four patients (14.81%) in group A, four patients (16%) in group B, and three (14.28%) patients in group C. Nine patients (33.33%) in group A, seven patients (28%) in group B and 18 (85.71%) patients in group C did not respond to immunotherapy.

Conclusions: Intralesional immunotherapy by both vaccines is a promising, effective, and safe treatment modality with MMR having slight edge.

Citing Articles

Systematic Review of Intralesional Therapies for Cutaneous Warts.

Mullen S, Myers E, Brenner R, Nguyen K, Harper T, Welsh D JID Innov. 2024; 4(3):100264.

PMID: 38585192 PMC: 10990969. DOI: 10.1016/j.xjidi.2024.100264.

Efficacy and Safety Profile of Tuberculin Protein Purified Derivative Injection As Immunotherapy For the Treatment of Cutaneous and Anogenital Warts: A Review Article.

Achdiat P, Suwarsa O, Hidayat Y, Shafiee M, Dwiyana R, Hindritiani R Immunotargets Ther. 2024; 13:123-150.

PMID: 38476374 PMC: 10929246. DOI: 10.2147/ITT.S446938.

Efficacy and safety of local candida immunotherapy in recalcitrant warts in pediatric kidney transplantation: A case report.

Acharya R, Bush R, Johns F, Upadhyay K World J Transplant. 2023; 13(4):201-207.

PMID: 37388391 PMC: 10303413. DOI: 10.5500/wjt.v13.i4.201.

References

Kus S, Ergun T, Gun D, Akin O . Intralesional tuberculin for treatment of refractory warts. J Eur Acad Dermatol Venereol. 2005; 19(4):515-6. DOI: 10.1111/j.1468-3083.2004.01176.x. View

Dasher D, Burkhart C, Morrell D . Immunotherapy for childhood warts. Pediatr Ann. 2009; 38(7):373-9. DOI: 10.3928/00904481-20090622-06. View

Horn T, Johnson S, Helm R, Roberson P . Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005; 141(5):589-94. DOI: 10.1001/archderm.141.5.589. View

Gamil H, Elgharib I, Nofal A, Abd-Elaziz T . Intralesional immunotherapy of plantar warts: report of a new antigen combination. J Am Acad Dermatol. 2010; 63(1):40-3. DOI: 10.1016/j.jaad.2009.07.023. View

Gupta S, Malhotra A, Verma K, Sharma V . Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: an open label pilot study. J Eur Acad Dermatol Venereol. 2008; 22(9):1089-93. DOI: 10.1111/j.1468-3083.2008.02719.x. View

Awal G, Kaur S . Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. J Clin Aesthet Dermatol. 2018; 11(5):15-20. PMC: 5955628. View

Eassa B, Abou-Bakr A, El-Khalawany M . Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther. 2011; 24(1):137-43. DOI: 10.1111/j.1529-8019.2010.01388.x. View

Nofal A, Nofal E . Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010; 24(10):1166-70. DOI: 10.1111/j.1468-3083.2010.03611.x. View

Shaheen M, Salem S, Fouad D, El-Fatah A . Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Dermatol Ther. 2015; 28(4):194-200. DOI: 10.1111/dth.12230. View

10.

Signore R . Candida albicans intralesional injection immunotherapy of warts. Cutis. 2002; 70(3):185-92. View

11.

Na C, Choi H, Song S, Kim M, Shin B . Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for warts. Clin Exp Dermatol. 2014; 39(5):583-9. DOI: 10.1111/ced.12369. View

12.

King M, Johnson S, Horn T . Intralesional immunotherapy for genital warts. Arch Dermatol. 2005; 141(12):1606-7. DOI: 10.1001/archderm.141.12.1606. View

13.

Bacelieri R, Johnson S . Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005; 72(4):647-52. View

14.

Johnson S, Roberson P, Horn T . Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001; 137(4):451-5. View

15.

Clifton M, Johnson S, Roberson P, Kincannon J, Horn T . Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003; 20(3):268-71. DOI: 10.1046/j.1525-1470.2003.20318.x. View

16.

Lichon V, Khachemoune A . Plantar warts: a focus on treatment modalities. Dermatol Nurs. 2007; 19(4):372-5. View

17.

de Villiers E, Fauquet C, Broker T, Bernard H, Zur Hausen H . Classification of papillomaviruses. Virology. 2004; 324(1):17-27. DOI: 10.1016/j.virol.2004.03.033. View

18.

Johnson S, Horn T . Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol. 2004; 3(3):263-5. View

19.

Saoji V, Lade N, Gadegone R, Bhat A . Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol. 2016; 82(1):42-6. DOI: 10.4103/0378-6323.171650. View